News & Events about Wave Life Sciences Ltd.
53% mean exon skipping and PN chemistry improved pharmacology of WVE-N531 compared with Waves first-generation DMD program demonstrated high muscle concentrations with a mean of 42 micrograms/gram WVE-N531 appeared safe and well tolerated Third Wave clinical trial evaluating a PN chemistry-...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive ...
Globe Newswire
4 months ago
WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes IND-enabling activities for WVE-006 are underway and Wave expects to submit clinical ...
Globe Newswire
4 months ago
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentationCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments ...
Thinking about buying stock in Unity Biotechnology, Payoneer Global, Toast, Wave Life Sciences, or Hippo? Thinking about buying stock in Unity Biotechnology, Payoneer Global, Toast, Wave Life Sciences, or Hippo? PR Newswire NEW YORK, Aug. 12, 2022 NEW YORK, Aug. 12, 2022 /PRNewswire...